Showing results (331-340 of 830) with videos related to
Sort By:
Pageof 83
Pharmacogenetics|July 2, 2003
NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking womenOlga L van der Hel, Petra H M Peeters, David W Hein, et al.Pharmacogenetics|July 2, 2003
GSTP1 A1578G (Ile105Val) polymorphism in benzidine-exposed workers: an association with cytological grading of exfoliated urothelial cellsQingwen Ma, Guofang Lin, Yiqiu Qin, et al.Pharmacogenetics|July 2, 2003
Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjectsEva-Maria D Nielsen, Lars Hansen, Søren M Echwald, et al.Pharmacogenetics|October 23, 2001
Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjectsL H Puckey, B L KnightPharmacogenetics|October 1, 1992
Metabolic, molecular genetic and toxicological aspects of the acetylation polymorphism in inbred miceG N Levy, K J Martell, J H DeLeon, et al.Pharmacogenetics|October 1, 1992
Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variantsD Hickman, A Risch, J P Camilleri, et al.Pharmacogenetics|October 1, 1992
Interindividual variability of coumarin 7-hydroxylation in healthy volunteersA Rautio, H Kraul, A Kojo, et al.Pharmacogenetics|October 1, 1992
A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratioG Tybring, L BertilssonPharmacogenetics|December 1, 1992
The pharmacogenetics of chemical carcinogenesisJ R Idle, M Armstrong, A V Boddy, et al.Pharmacogenetics|December 1, 1992
Epidemiology and pathophysiology of ethanol-associated gastrointestinal cancerH K Seitz, U A Simanowski, B R OsswaldPageof 83